With the rapid growth of personalized medicine and other technologies in the last five years, demand for liposomal drug products has reached an all time high. Due to the influx of business, we are excited to announce that we are beginning a large-scale expansion project that will allow us to meet industry demand and better serve our existing partners.
A $25 million dollar expansion project is in the works at Exelead. Read more about this project—and the company's rapid growth—in an exclusive interview with CEO John Rigg, published on insideindianabusiness.com.
"Exelead says it will remain focused on small batch production, where the company’s agility is paramount. Once it transfers in a molecule, the company can deliver a formulated drug product for clinical use within four months."
[/col] [col-1-6 data-mobile="hidden"] [/col] [/grid]